Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatol Baltim Md. 2023;78(6):1966–86.

Article  Google Scholar 

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335.

Article  PubMed  Google Scholar 

Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocr Rev. 2020;41(1):bnz009.

Article  PubMed  Google Scholar 

Mellemkjær A, Kjær MB, Haldrup D, Grønbæk H, Thomsen KL. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:28–34.

Article  PubMed  Google Scholar 

Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691–705.

Article  CAS  PubMed  Google Scholar 

Zhang L, Shi Y, Liang B, Li X. An overview of the cholesterol metabolism and its proinflammatory role in the development of MASLD. Hepatol Commun. 2024;8(5):e0434.

Article  PubMed  PubMed Central  Google Scholar 

Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3):726–35.

Article  CAS  PubMed  Google Scholar 

Lechner K, McKenzie AL, Kränkel N, Von Schacky C, Worm N, Nixdorff U, et al. High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, Atherogenic Dyslipidemia, and inflammation. Metab Syndr Relat Disord. 2020;18(4):176–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bril F, Lomonaco R, Orsak B, Ortiz-Lopez C, Webb A, Tio F, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology. 2014;59(6):2178–87.

Article  CAS  PubMed  Google Scholar 

Armstrong MJ, Hazlehurst JM, Hull D, Guo K, Borrows S, Yu J, et al. Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab. 2014;16(7):651–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatol Baltim Md. 2012;55(5):1389–97.

Article  CAS  Google Scholar 

Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta Int J Clin Chem. 2007;380(1–2):24–30.

Article  CAS  Google Scholar 

Jamali R, Razavizade M, Arj A, Aarabi MH. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease. World J Gastroenterol. 2016;22(21):5096–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wree A, McGeough MD, Peña CA, Schlattjan M, Li H, Inzaugarat ME, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med Berl Ger. 2014;92(10):1069–82.

Article  CAS  Google Scholar 

Arrese M, Cabrera D, Kalergis AM, Feldstein AE. Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci. 2016;61(5):1294–303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang MH, Sung J, Gwak GY. The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. J Clin Lipidol. 2016;10(2):289–98.

Article  PubMed  Google Scholar 

Hwang DH, Kim JA, Lee JY. Mechanisms for the activation of toll-like receptor 2/4 by saturated fatty acids and inhibition by docosahexaenoic acid. Eur J Pharmacol. 2016;785:24–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin Chim Acta. 2012;413(1):3–14.

Article  CAS  PubMed  Google Scholar 

Curtiss LK, Tobias PS. Emerging role of toll-like receptors in atherosclerosis. J Lipid Res. 2009;50:S340–5.

Article  PubMed  PubMed Central  Google Scholar 

Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.

Article  PubMed  Google Scholar 

Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla VM. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr. 2017;11(Suppl 1):S209–16.

Article  PubMed  Google Scholar 

Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016;6(1):33386.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230(2):258–67.

Article  CAS  PubMed  Google Scholar 

Faasse S, Braun H, Vos M. The role of NAFLD in cardiometabolic disease: an update. F1000Research. 2018;7:170.

Article  PubMed  PubMed Central  Google Scholar 

Pais R, Giral P, Khan JF, Rosenbaum D, Housset C, Poynard T, et al. Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol. 2016;65(1):95–102.

Article  CAS  PubMed  Google Scholar 

Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver Disease and Cardiovascular Risk: A Scientific Statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–85.

Article  CAS  PubMed  Google Scholar 

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European society of cardiology and 12 medical societies with the special contribution of the european association of preventive cardiology (EAPC). Eur Heart J. 2021;42(34):3227–337.

Article  PubMed  Google Scholar 

Nabi O, Lapidus N, Boursier J, de Ledinghen V, Petit JM, Kab S, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatol Baltim Md. 2023;78(1):272–83.

Article  Google Scholar 

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation [Internet]. 2019[cited 2024 Jul 24];140(11). Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000677. Accessed 24 Jul 2024.

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797.

Article  PubMed  Google Scholar 

Tacke F, Horn P, Wong VWS, Ratziu V, Bugianesi E, Francque S, et al. EASL–EASD–EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol [Internet]. 2024[cited 2024 Jul 10];0(0). Available from: https://www.journal-of-hepatology.eu/article/S0168-8278(24)00329-5/fulltext. Accessed 10 Jul 2024

Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score